This information is intended for US healthcare professionals For Patients


View published articles from peer-reviewed journals


Vibegron for the treatment of patients with dry and wet overactive bladder: a subgroup analysis from the EMPOWUR trial.
Int J Clin Pract. 2022;2022:(9 pages). doi:10.1155/2022/6475014
Staskin D, Frankel J, Varano S, et al.
An evaluation of the efficacy and safety of vibegron in the treatment of overactive bladder.
Ther Clin Risk Manag. 2022;18:171-182. doi:10.2147/TCRM.S310371
Frankel J, Staskin D, Varano S, Kennelly MJ, Jankowich RA, Haag-Molkenteller C.
Interpretation of the meaningfulness of symptom reduction with vibegron in patients with overactive bladder: analyses from EMPOWUR.
Adv Ther. 2022;39:959-970. doi:10.1007/s12325-021-01972-8
Frankel J, Staskin D, Varano S, et al.
Effects of vibegron on ambulatory blood pressure in patients with overactive bladder: results from a double-blind, placebo-controlled trial.
Blood Press Monit. 2022;27(2):128-134. doi:10.1097/MBP.0000000000000572
Weber MA, Haag-Molkenteller C, King J, Walker A, Mudd Jr PN, White WB.


Vibegron improves quality-of-life measures in patients with overactive bladder: patient-reported outcomes from the EMPOWUR study.
Int J Clin Pract. 2021;75(5):e13937. doi:10.1111/ijcp.13937
Frankel J, Varano S, Staskin D, Shortino D, Jankowich R, Mudd PN Jr.
Efficacy and safety of once-daily vibegron for treatment of overactive bladder in patients aged ≥65 and ≥75 years: subpopulation analysis from the EMPOWUR randomized, international, phase Ill study.
Drugs Aging. 2021;38:137-146. doi:10.1007/s40266-020-00829-z
Varano S, Staskin D, Frankel J, Shortino D, Jankowich R, Mudd PN Jr.


Once-daily vibegron 75 mg for overactive bladder: long-term safety and efficacy from a double-blind extension study of the international phase 3 trial (EMPOWUR).
J Urol. Published online December 28, 2020. doi:10.1097/JU.0000000000001574
Staskin D, Frankel J, Varano S, Shortino D, Jankowich R, Mudd PN. 
Vibegron 50 mg is the optimal algorithm in the pharmacologic management of overactive bladder: outcomes from a systematic review and meta-analysis.
Int Urol Nephrol. 2020;52(12):2215-2221. doi:10.1007/s11255-020-02536-5
Jian Z, Yuan C, Li H, Zhang W, Wang K.
Evaluating vibegron for the treatment of overactive bladder.
Expert Opin Pharmacother. 2020 Sep 29:1-9. [Epub ahead of print] doi:10.1080/14656566.2020.1809652
Rechberger T, Wróbel A.
International phase III, randomized, double-blind, placebo and active controlled study to evaluate the safety and efficacy of vibegron in patients with symptoms of overactive bladder: EMPOWUR.
J Urol. 2020;204(2):316-324. doi:10.1097/JU.0000000000000807
Staskin D, Frankel J, Varano S, Shortino D, Jankowich R, Mudd PN Jr.
Effects of vibegron, a novel β3-adrenoceptor agonist, and its combination with imidafenacin or silodosin in a rat with partial bladder outlet obstruction.
Eur J Pharmacol. Published online July 5, 2020. doi:10.1016/j.ejphar.2020.173096
Maruyama I, Yamamoto S, Tsuchioka K, Yamazaki T.
The efficacy and safety of vibegron in treating overactive bladder: a systematic review and pooled analysis of randomized controlled trials.
Neurourol Urodyn. 2020;39(5):1255-1263. doi:10.1002/nau.24387
Shi H, Chen H, Zhang Y, Cui Y.
Efficacy of vibegron, a novel β3-adrenoreceptor agonist, on severe urgency urinary incontinence related to overactive bladder: post hoc analysis of a randomized, placebo-controlled, double-blind, comparative phase 3 study.
BJU Int. 2020;125(5):709-717. doi:10.1111/bju.15020
Yoshida M, Takeda M, Gotoh M, et al.


Efficacy of novel β3-adrenoreceptor agonist vibegron on nocturia in patients with overactive bladder: a post-hoc analysis of a randomized, double-blind, placebo-controlled phase 3 study.
Int J Urol. 2019;26(3):369-375. doi:10.1111/iju.13877
Yoshida M, Takeda M, Gotoh M, et al.
Effects of the combination of vibegron and imidafenacin on bladder function in urethane-anesthetized rats.
Eur J Pharmacol. Published online December 1, 2019. doi:10.1016/j.ejphar.2019.172727
Yamazaki T, Maruyama I.
Vibegron (RVT-901/MK-4618/KRP-114V) administered once daily as monotherapy or concomitantly with tolterodine in patients with an overactive bladder: a multicenter, phase IIb, randomized, double-blind, controlled trial.
Eur Urol. 2019;75(2):274-282. doi:10.1016/j.eururo.2018.10.006
Mitcheson HD, Samanta S, Muldowney K, et al.


Vibegron: first global approval.
Drugs. 2018;78(17):1835-1839. doi:10.1007/s40265-018-1006-3
Keam SJ.
Synthesis of vibegron enabled by a ketoreductase rationally designed for high pH dynamic kinetic reduction.
Angew Chem Int Ed Engl. 2018;57(23):6863-6867. doi:10.1002/anie.201802791
Xu F, Kosjek B, Cabirol FL, et al.
Vibegron, a novel potent and selective β3-adrenoreceptor agonist, for the treatment of patients with overactive bladder: a randomized, double-blind, placebo-controlled phase 3 study.
Eur Urol. 2018;73(5):783-790. doi:10.1016/j.eururo.2017.12.022
Yoshida M, Takeda M, Gotoh M, Nagai S, Kurose T.
Long‐term safety and efficacy of the novel β3‐adrenoreceptor agonist vibegron in Japanese patients with overactive bladder: a phase III prospective study.
Int J Urol. 2018;25(7):668-675. doi:10.1111/iju.13596
Yoshida M, Kakizaki H, Takahashi S, Nagai S, Kurose T.


2D-QSAR and 3D-QSAR/CoMSIA studies on a series of (R)-2-((2-(1H-indol-2-yl)ethyl)amino)-1-phenylethan-1-ol with human β3-adrenergic activity.
Molecules. 2017;22(3):404. doi:10.3390/molecules2203040
Apablaza G, Montoya L, Morales-Verdejo C, et al.
Pharmacological characterization of a novel beta 3 adrenergic agonist, vibegron: evaluation of antimuscarinic receptor selectivity for combination therapy for overactive bladder.
J Pharmacol Exp Ther. 2017;360(2):346-355. doi:10.1124/jpet.116.237313
Di Salvo J, Nagabukuro H, Wickham LA, et al.


Discovery of vibegron: a potent and selective β3-adrenergic receptor agonist for the treatment of overactive bladder.
J Med Chem. 2016;59(2):609-623. doi:10.1021/acs.jmedchem.5b01372
Edmondson SD, Zhu C, Kar NM, et al.

Tell us what interests you

How interested are you in learning more about the following topics?

The role of β3-adrenoreceptor agonists in treating patients with OAB
Comorbidities among patients with OAB
Reducing the potential risk of drug-drug interactions
Clinical burden of OAB
Economic burden of OAB


We’ve received your completed survey. Thanks for participating.


Thank You.

We’ve received your inquiry. Thank you for contacting Urovant Sciences Medical Affairs. We will contact you shortly.


Take Survey

Welcome to
Urovant Sciences Medical Affairs

This site is intended as an educational resource for U.S. healthcare providers. The content may include information about products or potential uses that have not been approved by the U.S. Food and Drug Administration.

This information is not intended to be promotional or deliver medical advice.

Choose an option:

I’m a U.S. healthcare professional I’m a U.S. patient or caregiver